A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width
Background This study aims to investigate the prognostic value of the ratio of hemoglobin–RDW (HRR) at diagnosis, in terms of overall survival (OS) and progression-free survival in patients with advanced non-small cell lung cancer (NSCLC). Methods Patients with metastatic NCCLC who attended two sepa...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2019-07, Vol.24 (7), p.798-806 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 806 |
|---|---|
| container_issue | 7 |
| container_start_page | 798 |
| container_title | International journal of clinical oncology |
| container_volume | 24 |
| creator | Bozkaya, Yakup Kurt, Bediz Gürler, Fatih |
| description | Background
This study aims to investigate the prognostic value of the ratio of hemoglobin–RDW (HRR) at diagnosis, in terms of overall survival (OS) and progression-free survival in patients with advanced non-small cell lung cancer (NSCLC).
Methods
Patients with metastatic NCCLC who attended two separate medical oncology clinics between April 2013 and December 2017 were retrospectively screened. HRR was calculated as Hgb (g/dL) divided by the RDW (%). Patients were assigned to either the low HRR group or high HRR group.
Results
A total of 153 patients were included in the study. The cuff-value for HRR was taken as 0.88. Among the low and high HRR groups, Glasgow prognostic scores (GPS), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and weight loss were statistically significantly different (
p
|
| doi_str_mv | 10.1007/s10147-019-01417-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2184144645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2184144645</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-7c0aae2ff1ce07f7690dab0f08140ee5c152ffc68d5d6b4e7e0c52e12c946d953</originalsourceid><addsrcrecordid>eNp9kU1vFSEYhYmxsbX6B1wYEjdusC8MM8y4axq_kibd1DVh4J17aWbgCozWfy_TWzVx4YKP5Dzn8JJDyCsO7ziAusgcuFQM-FCX5IrdPyFnXDaKKaXE03pvJGdDJ9pT8jznOwCuulY8I6cNqL7pOZyR9ZIeUtyFmIu39GCSWbBgoj5Q476bYNHREAPLi5lnarFu8xp21G5Sek_LHmkyxUcaJ7rHJe7mOPrASmSpWh8MzueS_LhWKtAf3pX9C3IymTnjy8fznHz9-OH26jO7vvn05erymtlmGApTFoxBMU3cIqhJdQM4M8IEPZeA2FreVtF2vWtdN0pUCLYVyIUdZOeGtjknb4-59Y_fVsxFLz5vM5mAcc1a8F5yKTu5oW_-Qe_imkKdbqMaCWLo-0qJI2VTzDnhpA_JLyb91Bz0Voo-lqJrKfqhFH1fTa8fo9dxQffH8ruFCjRHIFcp7DD9ffs_sb8A_eWZSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2183402988</pqid></control><display><type>article</type><title>A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width</title><source>SpringerLink Journals - AutoHoldings</source><creator>Bozkaya, Yakup ; Kurt, Bediz ; Gürler, Fatih</creator><creatorcontrib>Bozkaya, Yakup ; Kurt, Bediz ; Gürler, Fatih</creatorcontrib><description>Background
This study aims to investigate the prognostic value of the ratio of hemoglobin–RDW (HRR) at diagnosis, in terms of overall survival (OS) and progression-free survival in patients with advanced non-small cell lung cancer (NSCLC).
Methods
Patients with metastatic NCCLC who attended two separate medical oncology clinics between April 2013 and December 2017 were retrospectively screened. HRR was calculated as Hgb (g/dL) divided by the RDW (%). Patients were assigned to either the low HRR group or high HRR group.
Results
A total of 153 patients were included in the study. The cuff-value for HRR was taken as 0.88. Among the low and high HRR groups, Glasgow prognostic scores (GPS), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and weight loss were statistically significantly different (
p
< 0.05). OS was found to be 5.6 months in the low HRR group and 13.9 months in the high HRR group (
p
< 0.001) while PFS was 5.1 months and 8.6 months in these two groups, respectively (
p
< 0.001). Univariate and multivariate analyses revealed that low HRR was an independent factor, predictive of both OS (
p
= 0.03, Hazard Ratio (HR) = 1.607, 95% CI = 1.041–2.480) and PFS (
p
< 0.001, HR = 2.635, 95% CI = 1.667–4.166) in advanced NSCLC.
Conclusion
This is the first study to show that low HRR is associated with poor OS and PFS in patients with advanced NSCLC. Thus, hemoglobin and RDW which can be easily measured in routine practice may be used as a prognostic tool in these patients.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-019-01417-x</identifier><identifier>PMID: 30783810</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Cancer Research ; Hemoglobin ; Lung cancer ; Medicine ; Medicine & Public Health ; Metastases ; Non-small cell lung carcinoma ; Oncology ; Original Article ; Surgical Oncology</subject><ispartof>International journal of clinical oncology, 2019-07, Vol.24 (7), p.798-806</ispartof><rights>Japan Society of Clinical Oncology 2019</rights><rights>International Journal of Clinical Oncology is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-7c0aae2ff1ce07f7690dab0f08140ee5c152ffc68d5d6b4e7e0c52e12c946d953</citedby><cites>FETCH-LOGICAL-c399t-7c0aae2ff1ce07f7690dab0f08140ee5c152ffc68d5d6b4e7e0c52e12c946d953</cites><orcidid>0000-0002-0180-8349</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-019-01417-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-019-01417-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30783810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bozkaya, Yakup</creatorcontrib><creatorcontrib>Kurt, Bediz</creatorcontrib><creatorcontrib>Gürler, Fatih</creatorcontrib><title>A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
This study aims to investigate the prognostic value of the ratio of hemoglobin–RDW (HRR) at diagnosis, in terms of overall survival (OS) and progression-free survival in patients with advanced non-small cell lung cancer (NSCLC).
Methods
Patients with metastatic NCCLC who attended two separate medical oncology clinics between April 2013 and December 2017 were retrospectively screened. HRR was calculated as Hgb (g/dL) divided by the RDW (%). Patients were assigned to either the low HRR group or high HRR group.
Results
A total of 153 patients were included in the study. The cuff-value for HRR was taken as 0.88. Among the low and high HRR groups, Glasgow prognostic scores (GPS), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and weight loss were statistically significantly different (
p
< 0.05). OS was found to be 5.6 months in the low HRR group and 13.9 months in the high HRR group (
p
< 0.001) while PFS was 5.1 months and 8.6 months in these two groups, respectively (
p
< 0.001). Univariate and multivariate analyses revealed that low HRR was an independent factor, predictive of both OS (
p
= 0.03, Hazard Ratio (HR) = 1.607, 95% CI = 1.041–2.480) and PFS (
p
< 0.001, HR = 2.635, 95% CI = 1.667–4.166) in advanced NSCLC.
Conclusion
This is the first study to show that low HRR is associated with poor OS and PFS in patients with advanced NSCLC. Thus, hemoglobin and RDW which can be easily measured in routine practice may be used as a prognostic tool in these patients.</description><subject>Cancer Research</subject><subject>Hemoglobin</subject><subject>Lung cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Surgical Oncology</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kU1vFSEYhYmxsbX6B1wYEjdusC8MM8y4axq_kibd1DVh4J17aWbgCozWfy_TWzVx4YKP5Dzn8JJDyCsO7ziAusgcuFQM-FCX5IrdPyFnXDaKKaXE03pvJGdDJ9pT8jznOwCuulY8I6cNqL7pOZyR9ZIeUtyFmIu39GCSWbBgoj5Q476bYNHREAPLi5lnarFu8xp21G5Sek_LHmkyxUcaJ7rHJe7mOPrASmSpWh8MzueS_LhWKtAf3pX9C3IymTnjy8fznHz9-OH26jO7vvn05erymtlmGApTFoxBMU3cIqhJdQM4M8IEPZeA2FreVtF2vWtdN0pUCLYVyIUdZOeGtjknb4-59Y_fVsxFLz5vM5mAcc1a8F5yKTu5oW_-Qe_imkKdbqMaCWLo-0qJI2VTzDnhpA_JLyb91Bz0Voo-lqJrKfqhFH1fTa8fo9dxQffH8ruFCjRHIFcp7DD9ffs_sb8A_eWZSg</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Bozkaya, Yakup</creator><creator>Kurt, Bediz</creator><creator>Gürler, Fatih</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0180-8349</orcidid></search><sort><creationdate>20190701</creationdate><title>A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width</title><author>Bozkaya, Yakup ; Kurt, Bediz ; Gürler, Fatih</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-7c0aae2ff1ce07f7690dab0f08140ee5c152ffc68d5d6b4e7e0c52e12c946d953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cancer Research</topic><topic>Hemoglobin</topic><topic>Lung cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bozkaya, Yakup</creatorcontrib><creatorcontrib>Kurt, Bediz</creatorcontrib><creatorcontrib>Gürler, Fatih</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bozkaya, Yakup</au><au>Kurt, Bediz</au><au>Gürler, Fatih</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>24</volume><issue>7</issue><spage>798</spage><epage>806</epage><pages>798-806</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
This study aims to investigate the prognostic value of the ratio of hemoglobin–RDW (HRR) at diagnosis, in terms of overall survival (OS) and progression-free survival in patients with advanced non-small cell lung cancer (NSCLC).
Methods
Patients with metastatic NCCLC who attended two separate medical oncology clinics between April 2013 and December 2017 were retrospectively screened. HRR was calculated as Hgb (g/dL) divided by the RDW (%). Patients were assigned to either the low HRR group or high HRR group.
Results
A total of 153 patients were included in the study. The cuff-value for HRR was taken as 0.88. Among the low and high HRR groups, Glasgow prognostic scores (GPS), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and weight loss were statistically significantly different (
p
< 0.05). OS was found to be 5.6 months in the low HRR group and 13.9 months in the high HRR group (
p
< 0.001) while PFS was 5.1 months and 8.6 months in these two groups, respectively (
p
< 0.001). Univariate and multivariate analyses revealed that low HRR was an independent factor, predictive of both OS (
p
= 0.03, Hazard Ratio (HR) = 1.607, 95% CI = 1.041–2.480) and PFS (
p
< 0.001, HR = 2.635, 95% CI = 1.667–4.166) in advanced NSCLC.
Conclusion
This is the first study to show that low HRR is associated with poor OS and PFS in patients with advanced NSCLC. Thus, hemoglobin and RDW which can be easily measured in routine practice may be used as a prognostic tool in these patients.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>30783810</pmid><doi>10.1007/s10147-019-01417-x</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-0180-8349</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2019-07, Vol.24 (7), p.798-806 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2184144645 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Cancer Research Hemoglobin Lung cancer Medicine Medicine & Public Health Metastases Non-small cell lung carcinoma Oncology Original Article Surgical Oncology |
| title | A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T18%3A05%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prognostic%20parameter%20in%20advanced%20non-small%20cell%20lung%20cancer:%20the%20ratio%20of%20hemoglobin-to-red%20cell%20distribution%20width&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Bozkaya,%20Yakup&rft.date=2019-07-01&rft.volume=24&rft.issue=7&rft.spage=798&rft.epage=806&rft.pages=798-806&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-019-01417-x&rft_dat=%3Cproquest_cross%3E2184144645%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2183402988&rft_id=info:pmid/30783810&rfr_iscdi=true |